# Synergetic B-cell Immodulation in SLE

> **NCT02284984** · PHASE2 · COMPLETED · sponsor: **Leiden University Medical Center** · enrollment: 16 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Rituximab with belimumab

## Key facts

- **NCT ID:** NCT02284984
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284984, "Synergetic B-cell Immodulation in SLE". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02284984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*